Orchard Therapeutics Management

Management criteria checks 3/4

Orchard Therapeutics' CEO is Bobby Gaspar, appointed in Mar 2020, has a tenure of 3.83 years. total yearly compensation is $1.45M, comprised of 39.6% salary and 60.4% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth €561.14K. The average tenure of the management team and the board of directors is 2.7 years and 5.6 years respectively.

Key information

Bobby Gaspar

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage	39.6%
CEO tenure	3.8yrs
CEO ownership	0.2%
Management average tenure	2.7yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bobby Gaspar's remuneration changed compared to Orchard Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$73m
Jun 30 2023	n/a	n/a	-US$85m
Mar 31 2023	n/a	n/a	-US$124m
Dec 31 2022	US$1m	US$573k	-US$151m
Sep 30 2022	n/a	n/a	-US$179m
Jun 30 2022	n/a	n/a	-US$168m
Mar 31 2022	n/a	n/a	-US$154m
Dec 31 2021	US$4m	US$605k	-US$145m
Sep 30 2021	n/a	n/a	-US$142m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$137m
Dec 31 2020	US$4m	US$543k	-US$152m
Sep 30 2020	n/a	n/a	-US$164m
Jun 30 2020	n/a	n/a	-US$180m
Mar 31 2020	n/a	n/a	-US$183m
Dec 31 2019	US$921k	US$344k	-US$163m
Sep 30 2019	n/a	n/a	-US$143m
Jun 30 2019	n/a	n/a	-US$140m
Mar 31 2019	n/a	n/a	-US$246m
Dec 31 2018	US$2m	US$338k	-US$230m

Compensation vs Market: Bobby's total compensation ($USD1.45M) is above average for companies of similar size in the German market ($USD1.07M).

Compensation vs Earnings: Bobby's compensation has been consistent with company performance over the past year.

CEO

Bobby Gaspar (60 yo)

3.8yrs

Tenure

US$1,447,526

Compensation

Dr. Hubert Baburaj Gaspar, M.D. Ph.D. also known as Bobby, has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hubert Gaspar	CEO, Member of Scientific Advisory Board & Executive Director	3.8yrs	US$1.45m	0.16% $ 561.1k
Frank Thomas	President & COO	4yrs	US$1.21m	0.040% $ 141.1k
Nicoletta Loggia	Chief Technical Officer	2.3yrs	no data	no data
Fulvio Mavilio	Chief Scientific Officer	2yrs	no data	no data
Renee Leck	Head of Investor Relations	no data	no data	no data
Benjamin Navon	Director of Corporate Communications	no data	no data	no data
John Cerio	Chief Human Resource Officer	no data	no data	no data
Robin Kenselaar	Senior VP & GM of EMEA Commercial Operations	5.2yrs	no data	no data
Braden Parker	Chief Commercial Officer	3yrs	no data	no data
Leslie Meltzer	Chief Medical Officer	2.3yrs	no data	no data
Christopher York	Company Secretary	1.9yrs	no data	no data

2.7yrs

Average Tenure

Experienced Management: OT10's management team is considered experienced (2.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Hubert Gaspar	CEO, Member of Scientific Advisory Board & Executive Director	7.9yrs	US$1.45m	0.16% $ 561.1k
James Arthur Geraghty	Independent Chairman	5.7yrs	US$107.72k	0.019% $ 68.0k
Marc Dunoyer	Independent Non-Executive Director	5.6yrs	US$71.72k	0.016% $ 57.0k
Charles Rowland	Independent Non-Executive Director	5.5yrs	US$90.72k	0.0054% $ 18.8k
Donald Kohn	Member of Scientific Advisory Board	no data	no data	no data
Alessandra Biffi	Member of Scientific Advisory Board	no data	no data	no data
Brian Bigger	Member of Scientific Advisory Board	no data	no data	no data
Simon Jones	Member of Scientific Advisory Board	no data	no data	no data
Adrian Thrasher	Member of Scientific Advisory Board	no data	no data	no data
David Williams	Member of Scientific Advisory Board	no data	no data	no data
Robert Wynn	Member of Scientific Advisory Board	no data	no data	no data
Harry Malech	Member of Scientific Advisory Board	no data	no data	no data

5.6yrs

Average Tenure

67yo

Average Age

Experienced Board: OT10's board of directors are considered experienced (5.6 years average tenure).

Orchard Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Insufficient new directors

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Insufficient new directors

Insufficient new directors

Recent updates

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

New major risk - Financial position

Insufficient new directors

Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy

Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Third quarter 2023 earnings released: US$1.55 loss per share (vs US$3.71 loss in 3Q 2022)

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023

New major risk - Shareholder dilution

Insufficient new directors

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq

Insufficient new directors

Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V.

Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Independent Non-Executive Director Jon Ellis has left the company

Orchard Therapeutics Announces Data Published in the New England Journal of Medicine Evaluating the Safety and Efficacy of Investigational Gene Therapy Products, Including OTL-101

Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™

Revenue misses expectations

Full year 2020 earnings released: US$1.53 loss per share (vs US$1.75 loss in FY 2019)

Orchard Therapeutics plc Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome

Orchard Therapeutics plc announced that it expects to receive $149.999996 million in funding from RA Capital Management, L.P., Avidity Partners Management LP, Casdin Capital, LLC, Farallon Capital Management, L.L.C., Citadel Enterprise Americas LLC and other investors

New 90-day high: €6.30

Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer

Orchard Therapeutics Secures Partnerships to Broaden Access to Libmeldy for Eligible Patients in Middle East & Turkey

Orchard Therapeutics Announces OTL-200 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by FDA for the Treatment of Metachromatic Leukodystrophy (MLD)

New 90-day high: €5.15

Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy

Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)

Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)

Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event

Orchard Therapeutics Announces Presentation of New Clinical Data At the Upcoming 62nd American Society of Hematology Annual Meeting

Revenue beats expectations

Orchard Therapeutics plc Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

Orchard Therapeutics Receives EMA Prime Designation for OTL-203 for the Treatment of MPS-I

New 90-day low: €3.24

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age